Terms: = Liver cancer AND GNAS, RP4-543J19_4, 2778, ENSG00000087460, NESP55, NESP, GSP, POH, GNASXL, GNAS1, C20orf45, dJ309F20_1_1, SCG6, GPSA, Gnas, dJ806M20_3_3, XL2, MGC33735, XL, PHP1A, GSA, AHO, XLalphas, PHP1B AND Prognosis
6294 results:
1. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
Dang J; Xu G; Guo G; Zhang H; Shang L
J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
[TBL] [Abstract] [Full Text] [Related]
2. Early detection and prognosis evaluation for hepatocellular carcinoma by circulating tumour DNA methylation: A multicentre cohort study.
Guo DZ; Huang A; Wang YC; Zhou S; Wang H; Xing XL; Zhang SY; Cheng JW; Xie KH; Yang QC; Ma CC; Li Q; Chen Y; Su ZX; Fan J; Liu R; Liu XL; Zhou J; Yang XR
Clin Transl Med; 2024 May; 14(5):e1652. PubMed ID: 38741204
[TBL] [Abstract] [Full Text] [Related]
3. DNA methylation regulator-based molecular subtyping and tumor microenvironment characterization in hepatocellular carcinoma.
Zhao J; Liu Z; Yang K; Shen S; Peng J
Front Immunol; 2024; 15():1333923. PubMed ID: 38736884
[TBL] [Abstract] [Full Text] [Related]
4. Transcript and protein signatures derived from shared molecular interactions across cancers are associated with mortality.
Zhao Y; Li X; Loscalzo J; Smelik M; Sysoev O; Wang Y; Mahmud AKMF; Mansour Aly D; Benson M
J Transl Med; 2024 May; 22(1):444. PubMed ID: 38734658
[TBL] [Abstract] [Full Text] [Related]
5. Precise planning based on 3D-printed dry-laboratory models can reduce perioperative complications of laparoscopic surgery for complex hepatobiliary diseases: a preoperative cohort study.
Yao WF; Huang XK; Fu TW; Jin L; Du CF; Gao ZY; Wang KD; Dai MG; Liu SY; Liu JW; Zhang CW; Liang L; Huang DS
BMC Surg; 2024 May; 24(1):148. PubMed ID: 38734630
[TBL] [Abstract] [Full Text] [Related]
6. The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 study.
Yang CX; Pan YX; Ye F; Zhu XD; Xue J; Li X; Yuan ZG; Zhang L; Xu L; Chen YJ; Wang NY; Sun HC; Liu XF;
Front Immunol; 2024; 15():1310239. PubMed ID: 38711515
[TBL] [Abstract] [Full Text] [Related]
7. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.
Zhang Y; Zhang H; Xu H; Wang Y; Feng L; Yi F
World J Surg Oncol; 2024 May; 22(1):122. PubMed ID: 38711095
[TBL] [Abstract] [Full Text] [Related]
8. Exploring the role of CDCA4 in liver hepatocellular carcinoma using bioinformatics analysis and experiments.
Liang C; Long K; Zheng W; Zhong R; Li Z; Zhu S; Gu S; Zhu C; Yang Y
Medicine (Baltimore); 2024 May; 103(18):e38028. PubMed ID: 38701314
[TBL] [Abstract] [Full Text] [Related]
9. The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors.
Sun W; Yin X; Liu X; Wei J; Yu M; Li W; Ding X; Chen J
Front Immunol; 2024; 15():1380477. PubMed ID: 38698848
[TBL] [Abstract] [Full Text] [Related]
10. Bortezomib in previously treated phosphatase and tension homology-deficient patients with advanced intrahepatic cholangiocarcinoma: An open-label, prospective and single-centre phase II trial.
Zeng TM; Jiang TY; Yang G; Cheng Z; Lou C; Wei W; Tao CJ; Hu S; Wang H; Cui XW; Tan YX; Dong LW; Wang HY; Yuan ZG
Clin Transl Med; 2024 May; 14(5):e1675. PubMed ID: 38689424
[TBL] [Abstract] [Full Text] [Related]
11. A retrospective clinical analysis of 11 cases of PEComa from different sites.
Yan J; Zhou D; Wang Y; Yang B; Wang Y; Zhang K; Zhang S; Zhang B; Meng Q; Lv Q
World J Surg Oncol; 2024 Apr; 22(1):116. PubMed ID: 38689335
[TBL] [Abstract] [Full Text] [Related]
12. Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma.
Zhu JQ; Liu JZ; Yang SW; Ren ZY; Ye XY; Liu Z; Li XL; Han DD; He Q
Front Endocrinol (Lausanne); 2024; 15():1306091. PubMed ID: 38686208
[TBL] [Abstract] [Full Text] [Related]
13. Preclinical evaluation of AGTR1-Targeting molecular probe for colorectal cancer imaging in orthotopic and liver metastasis mouse models.
Zhou K; Li G; Pan R; Xin S; Wen W; Wang H; Luo C; Han RPS; Gu Y; Tu Y
Eur J Med Chem; 2024 May; 271():116452. PubMed ID: 38685142
[TBL] [Abstract] [Full Text] [Related]
14. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders in pediatric transplantation: A prospective multicenter study in the United States.
Tajima T; Martinez OM; Bernstein D; Boyd SD; Gratzinger D; Lum G; Sasaki K; Tan B; Twist CJ; Weinberg K; Armstrong B; Desai DM; Mazariegos GV; Chin C; Fishbein TM; Tekin A; Venick RS; Krams SM; Esquivel CO
Pediatr Transplant; 2024 Jun; 28(4):e14763. PubMed ID: 38682750
[TBL] [Abstract] [Full Text] [Related]
15. Safety and tolerability of OP-724 in patients with haemophilia and liver cirrhosis due to HIV/HCV coinfection: an investigator-initiated, open-label, non-randomised, single-centre, phase I study.
Kimura K; Tanuma J; Kimura M; Imamura J; Yanase M; Ieiri I; Kurosaki M; Watanabe T; Endo T; Yotsuyanagi H; Gatanaga H
BMJ Open Gastroenterol; 2024 Apr; 11(1):. PubMed ID: 38677720
[TBL] [Abstract] [Full Text] [Related]
16. Paraneoplastic Syndromes in Hepatocellular Carcinoma, Epidemiology, and Survival: A Retrospective Seven Years Study.
Burciu C; Sirli R; Bende R; Vuletici D; Miutescu B; Moga T; Bende F; Popescu A; Sporea I; Koppandi O; Miutescu E; Iovanescu D; Danila M
Medicina (Kaunas); 2024 Mar; 60(4):. PubMed ID: 38674198
[No Abstract] [Full Text] [Related]
17. The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy.
Du J; Zhang E; Huang Z
Front Immunol; 2024; 15():1358306. PubMed ID: 38665910
[TBL] [Abstract] [Full Text] [Related]
18. Predicting the immunity landscape and prognosis with an NCLs signature in liver hepatocellular carcinoma.
Ji Z; Zhang C; Yuan J; He Q; Zhang X; Yang D; Xu N; Chu J
PLoS One; 2024; 19(4):e0298775. PubMed ID: 38662757
[TBL] [Abstract] [Full Text] [Related]
19. A preliminary study of optimal treatment response rates in patients undergoing hepatic arterial infusion chemotherapy combined with molecular targeting and immunotherapy.
Li M; Liao J; Wang L; Lv T; Sun Q; Xu Y; Guo Z; Quan M; Qin H; Yu H; Zhang K; Xing W; Yu H
Front Immunol; 2024; 15():1303259. PubMed ID: 38660298
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic analysis of hepatocellular carcinoma based on cuproptosis -associated lncRNAs.
Wei M; Lu L; Luo Z; Ma J; Wang J
BMC Gastroenterol; 2024 Apr; 24(1):142. PubMed ID: 38654165
[TBL] [Abstract] [Full Text] [Related]
[Next]
